Single IRB model will 'dramatically accelerate' treatment delivery, says NIH

By Melissa Fassbender

- Last updated on GMT

NIH makes progress on single IRB model
The National Institutes of Health (NIH) has reached a milestone in its goal of accelerating multisite clinical studies through a single institutional review board (IRB) model.

NIH’s National Center for Advancing Translational Sciences (NCATS) announced that all Clinical and Translational Science Awards (CTSA) Program sites have signed on to the NCATS Streamlined, Multisite, Accelerated Resources for Trials (SMART) IRB authorization agreement.

The NCATS SMART IRB authorization agreement was developed to establish a harmonized approach for roles and responsibilities of the single IRB and the participating sites​,” Michelle Culp, M.P.H., Director of Clinical Operations, Division of Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, told Outsourcing-Pharma.com.

Enabling all participating sites in a clinical study to rely on the ethics review of a single IRB will streamline the ethics review process, making it possible to initiate multisite studies faster​,” she added.

Moving forward, Culp said the next steps include collaborating with lead institutions on training, policies and procedures for implementing the SMART IRB Reliance Platform that can be used to support ethical review of multisite studies.

Addressing long-standing systemic challenges in multisite clinical trials, such as approval of a single protocol by multipleinstitutional review boards, will dramatically accelerate the delivery of new treatments to patients​,” said Culp.

Obtaining all CTSA Program hubs’ support for the SMART IRB authorization agreement isthe first milestone in a multi-step transformative initiative to provide a flexible platform that investigators can access nationwide to coordinate and streamline the ethics review process for their own multisite studies​.”

(Feature image: iStock/thamerpic)

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars